share_log

Molecular Partners Presents Interim Safety And Mechanistic Data From Ongoing Phase 1 Trial Of MP0317 For Treatment of Solid Tumors

Benzinga Real-time News ·  Nov 10, 2022 01:42
  • First clinical observation of tumor localized CD40 activation provided by MP0317
  • No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents
  • Dose escalation remains ongoing with study recruitment anticipated to complete in 1H 2023

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of positive interim results from the ongoing Phase 1 trial of the company's MP0317 (FAP X CD40) program for the treatment of solid tumors at...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment